Stockscreener 앱 받기
10.77
0.32%
-0.03
시간 외 거래:
10.77
전일 마감가:
$10.80
열려 있는:
$10.69
하루 거래량:
650.33K
Relative Volume:
0.60
시가총액:
$543.38M
수익:
-
순이익/손실:
$-156.39M
주가수익비율:
-2.9187
EPS:
-3.69
순현금흐름:
$-123.06M
1주 성능:
-3.28%
1개월 성능:
-9.16%
6개월 성능:
-20.55%
1년 성능:
-7.44%
1일 변동 폭
$10.51
$11.04
1주일 범위
$10.51
$11.30
52주 변동 폭
$7.30
$17.28
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
명칭
Kalvista Pharmaceuticals Inc
전화
(857) 999-0075
주소
200 CROSSING BOULEVARD, FRAMINGHAM, MA
KALV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
10.76 | 545.65M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.80 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
627.77 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.84 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.74 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-12-18 | 개시 | BofA Securities | Buy |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2019-07-29 | 개시 | SVB Leerink | Outperform |
| 2019-03-20 | 개시 | Needham | Buy |
| 2018-10-30 | 개시 | Jefferies | Buy |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 개시 | BTIG Research | Buy |
모두보기
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
Exit strategy if you’re trapped in KalVista Pharmaceuticals Inc.2025 Key Lessons & Free Reliable Trade Execution Plans - newser.com
Multi asset correlation models including KalVista Pharmaceuticals Inc.Trade Ideas & Real-Time Price Movement Reports - newser.com
Real time scanner hits for KalVista Pharmaceuticals Inc. explainedWeekly Stock Report & Free High Return Stock Watch Alerts - newser.com
Will KalVista Pharmaceuticals Inc. stock attract more institutional investors2025 Big Picture & Free Safe Capital Growth Stock Tips - newser.com
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025 - The Joplin Globe
How to track smart money flows in KalVista Pharmaceuticals Inc.Quarterly Portfolio Review & Breakout Confirmation Trade Signals - newser.com
What makes KalVista Pharmaceuticals Inc. stock attractive to growth fundsOil Prices & Verified Swing Trading Watchlist - newser.com
How KalVista Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Analyst Calls & Weekly Chart Analysis and Trade Guides - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock benefit from commodity supercycleJuly 2025 Snapshot & AI Powered Trade Plan Recommendations - newser.com
Why KalVista Pharmaceuticals Inc. (4XC1) stock is favored by hedge fundsQuarterly Growth Report & Weekly Top Performers Watchlists - newser.com
Using R and stats models for KalVista Pharmaceuticals Inc. forecastingJuly 2025 Pullbacks & Weekly Market Pulse Updates - newser.com
Can KalVista Pharmaceuticals Inc. (4XC1) stock sustain margin levelsQuarterly Earnings Summary & Reliable Price Breakout Signals - newser.com
Is KalVista Pharmaceuticals Inc. (4XC1) stock a defensive play amid uncertaintyTrade Entry Report & High Conviction Trade Alerts - newser.com
Will KalVista Pharmaceuticals Inc. stock reach Wall Street targetsCPI Data & Weekly Breakout Watchlists - newser.com
What market sentiment indicators show for KalVista Pharmaceuticals Inc. (4XC1) stockProduct Launch & Fast Momentum Entry Tips - newser.com
How strong is KalVista Pharmaceuticals Inc. (4XC1) stock earnings growthJuly 2025 PostEarnings & Step-by-Step Swing Trade Plans - newser.com
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will a bounce in KalVista Pharmaceuticals Inc. offer an exit2025 Support & Resistance & Daily Oversold Bounce Ideas - newser.com
How hedge fund analytics apply to KalVista Pharmaceuticals Inc. stockM&A Rumor & AI Driven Price Forecasts - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock keep high P E multiplesJuly 2025 Catalysts & Safe Entry Momentum Stock Tips - newser.com
KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs - MSN
Emerald Mutual Fund Advisers Trust Increases Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Emerald Advisers LLC Boosts Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Pass Below Fifty Day Moving AverageWhat's Next? - MarketBeat
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting - The Joplin Globe
(sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting - Business Wire
Kalvista Pharmaceuticals Inc (KALV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.29%
0.56%
자본화:
|
볼륨(24시간):